National Pension Service Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

National Pension Service boosted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 949,743 shares of the medical device company's stock after purchasing an additional 37,363 shares during the quarter. National Pension Service owned about 0.24% of DexCom worth $63,671,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company's stock valued at $6,186,539,000 after buying an additional 136,282 shares during the last quarter. Blair William & Co. IL boosted its stake in DexCom by 1.4% during the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company's stock valued at $628,684,000 after purchasing an additional 64,683 shares during the last quarter. Legal & General Group Plc increased its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after purchasing an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after buying an additional 353,019 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its stake in shares of DexCom by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company's stock worth $252,906,000 after buying an additional 20,400 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

NASDAQ DXCM traded down $0.39 during trading hours on Wednesday, hitting $68.61. The company had a trading volume of 5,138,619 shares, compared to its average volume of 3,907,170. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $26.80 billion, a price-to-earnings ratio of 41.08, a PEG ratio of 2.16 and a beta of 1.17. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm has a 50 day simple moving average of $69.66 and a 200 day simple moving average of $94.30.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DXCM shares. Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Baird R W cut DexCom from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 26th. Canaccord Genuity Group restated a "buy" rating and set a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. Oppenheimer lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.